(2)期间费用影响。报告期内，公司坚持创新驱动发展战略和团队激励建设，聚焦POCT产品的深度研发 与品质提升，推出满足不同细分领域和客户个性化需求的高质量产品，持续推进品牌建设和渠道推广， 研发费用、员工持股计划产生的股份支付费用增加，此外，汇率波动、金融市场存款利率下行导致的财 务性收益同比减少。以上导致利润下滑显著。 (3)非经营性损益的影响。上期受境外客户在新冠疫情期间的病毒检测产品订单于2024年度终止影响， 无需返还的500万美元订单预收款及代收运输费在2024年度转为收入，导致2024年净利润增加。报告期 内，公司未发生此类收入。 格隆汇2月27日丨博拓生物(688767.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入4.48亿 元，较上年同期减少19.85%；营业利润5005.38万元，较上年同期减少74.12%；归属于母公司所有者的 净利润4679.57万元，较上年同期减少72.39%；归属于母公司所有者的扣除非经常性损益的净利润 2498.15万元，较上年同期减少79.06%。 影响经营业绩的主要因素： (1)营业收入影响。2025年上半年，由于美国政府多次加征关税引发市场重大 ...

Core Viewpoint - Botao Bio is forecasting a significant decline in net profit for 2025, with an expected net profit of approximately 45 million yuan, representing a year-on-year decrease of about 73.45% [1] Revenue Impact - The company's revenue is expected to be adversely affected in the first half of 2025 due to multiple tariff increases imposed by the U.S. government, leading to a decline in exports to the U.S. [1] - Domestic demand for respiratory testing products and mosquito-borne disease products in Latin America has also decreased year-on-year, further impacting overall revenue [1] Expense Impact - The company is focusing on innovation and team incentives, which has led to increased research and development expenses and costs associated with employee stock ownership plans [1] - Financial income from foreign exchange gains and interest has decreased year-on-year, contributing to a significant decline in profits [1] Non-Operating Income Impact - In the previous period, the company benefited from a $5 million advance payment and transportation fees from overseas customers for COVID-19 testing products, which were recognized as revenue in 2024, leading to increased net profit [1] - The current reporting period did not experience similar non-operating income, which has negatively affected profit figures [1]

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. has demonstrated operational resilience amid challenges in the in vitro diagnostics (IVD) industry, including intensified centralized procurement and changes in the international trade environment, by actively adjusting its market strategies [1][3]. Financial Performance - In the first half of 2025, the company reported revenue of 230 million yuan and a net profit of 23.5862 million yuan after deducting non-recurring items [1]. Market Strategy - The company has adopted a "dual-wheel drive" strategy focusing on both international and domestic markets to address uncertainties in overseas markets, leading to a strong adaptability in overall operations despite performance fluctuations [1][3]. - In the domestic market, Anxu Biotechnology successfully obtained multiple medical device registration certificates, including for respiratory virus antigen detection and influenza virus antigen testing kits, targeting essential healthcare needs [1][2]. Business Expansion - The company has developed a dual-track model of "deepening B-end and breaking into C-end" by leveraging the "Anxu Ke" brand to expand into e-commerce, resulting in steady sales growth in home health management products [2]. - Anxu Biotechnology has established a "global network + localized service" system to strengthen its presence in traditional markets such as Europe, Oceania, Asia, and Africa, while also extending into emerging markets to mitigate single-market risks [2]. Diversification - The company is actively expanding into new fields while consolidating its traditional advantages in point-of-care testing (POCT). Its subsidiary, Taimengle, focuses on pet medical testing, developing over a hundred testing solutions for various infectious diseases and health monitoring [2]. - The company has launched the GluMate chronic disease management app, integrating existing POCT products into a comprehensive solution that includes hardware, software, and data services [2]. Industry Outlook - The global IVD market is projected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with strong growth expected in microfluidic technology and pet medical testing segments [3]. - Despite the overall pressure on the industry in the first half of 2025, the company has shown innovative vitality and resilience through its integrated supply chain, global layout, and diversified business strategies, laying a solid foundation for long-term healthy development [3].

Core Viewpoint - The company aims to enhance its AI capabilities and product offerings while maintaining a strong focus on technological innovation and efficiency improvements in its operations [1][2]. Group 1: Company Strategy and Innovation - The company is committed to deepening its research in AI and expanding its product matrix, with a focus on technology innovation mechanisms [1]. - The company has accumulated a vast database of desensitized data based on real specimen images, which is a core resource that is difficult for competitors to replicate [2]. - In 2024, the company participated in the development of four group standards and authored four academic works, further solidifying its technological leadership [2]. Group 2: Financial Performance - In a challenging environment for the medical device industry, the company achieved growth in both revenue and net profit in 2024, demonstrating strong operational resilience [2]. - The company implemented cost-reduction and efficiency-enhancement measures across procurement, manufacturing, and R&D, leading to a decrease in product costs [2]. - The sales proportion of high-margin reagents and consumables has gradually increased, resulting in an overall improvement in gross margin compared to the previous year [2]. Group 3: Market Expansion and Product Development - The company has installed its testing instruments in over 6,000 hospitals nationwide, with nearly 8,000 units in use, which supports the growth of high-margin reagent sales [3]. - The company has launched multiple POCT product series covering various health areas, and these products are being sold through various channels including e-commerce platforms and clinics [3]. - The company is actively building third-party IVD laboratories and developing a smart healthcare platform aimed at serving grassroots markets [4].